Zomagen Biosciences
CompanyUnited States
Zomagen Biosciences develops one asset, in phase 2 (VTX2735 in recurrent pericarditis). Mostly small molecule acting on NLRP3, NLRP3 inflammasome and inflammation; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 2
- Trials
- 0
- Signals
Pipeline
1Inhibitor of the NLRP3 inflammasome reducing systemic inflammation
Phase 2, Small molecule, NLRP3, NLRP3 inflammasome, recurrent pericarditis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials2
- Similar companies6